302 hot topic(s) found with the query "Ovarian cancer"
Implementing Cancer Genomics in State Health Agencies: Mapping Activities to an Implementation Science Outcome Framework.
Green Ridgely Fisk et al. Public health genomics 2020 Sep 1-12
(Posted: Sep-18-2020 9AM)
We identified state health agency activities addressing hereditary breast and ovarian cancer and Lynch syndrome by reviewing project narratives from Centers for Disease Control and Prevention Cancer Genomics Program funding recipients, leading discussions with state health agencies, and conducting an environmental scan.
Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions
AC Fahed et al, Nature Communications, August 20, 2020
(Posted: Aug-21-2020 9AM)
We study 80,928 individuals to examine whether polygenic background can modify penetrance of disease in tier 1 genomic conditions — familial hypercholesterolemia, hereditary breast and ovarian cancer, and Lynch syndrome. Among carriers of a monogenic risk variant, we estimate substantial gradients in disease risk based on polygenic background — the probability of disease by age 75 years ranged from 17% to 78% for coronary artery disease, 13% to 76% for breast cancer, and 11% to 80% for colon cancer.
A new test may better predict ovarian cancer survival
L Hopper, USC News, August 17, 2020
(Posted: Aug-20-2020 7AM)
Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants
DR Barnes et al, Genetics in Medicine, July 15, 2020
(Posted: Jul-17-2020 11AM)
We assessed the associations between population-based polygenic risk scores (PRS) for breast (BC) or epithelial ovarian cancer (EOC) with cancer risks for 18,935 BRCA1 and 12,339 BRCA2 pathogenic variant carriers of European ancestry. PRS are strongly associated with BC and EOC and predict substantial absolute risk differences at PRS distribution extremes.
Updates in BRCA testing for People of Ashkenazi Jewish Ancestry
L Steinmark, Jackson Labs, May 3, 2020
(Posted: May-07-2020 8AM)
For the past few decades, genetic providers and researchers have recognized the importance of the three BRCA founder mutations and were able to test specifically for them in individuals at risk, defined as having Ashkenazi ancestry and a personal or family history of breast and/or ovarian cancer.
Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History
AP Patel, JAMA Network Open, April 29, 2020
(Posted: Apr-30-2020 8AM)
In this cohort study of 49?738 participants in the UK Biobank, a pathogenic or likely pathogenic variant associated with the 3 tier 1 genomic conditions (BRCA, Lynch syndrome, FH) was identified in 0.9% of participants. These individuals had an increased risk of disease identified by gene sequencing that was not found through self-reported family history.
Association Between Genetically Proxied Inhibition of HMG-CoA Reductase and Epithelial Ovarian Cancer.
Yarmolinsky James et al. JAMA 2020 Feb (7) 646-655
(Posted: Feb-20-2020 9AM)
Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
Angeli Davide et al. International journal of molecular sciences 2020 Feb 21(3)
(Posted: Feb-19-2020 9AM)
Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline.
Konstantinopoulos Panagiotis A et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2020 Jan JCO1902960
(Posted: Jan-29-2020 8AM)
Women with identified dMMR should be offered FDA-approved treatment based on these results. Genetic evaluations should be conducted in conjunction with health care providers familiar with the diagnosis and management of hereditary cancer.
Mayo genomic database to use sequencing for 100K participants
G Slabodkin, Health Data Management, January 10, 2020
(Posted: Jan-13-2020 9AM)
The Mayo Clinic will build a library of genomic sequencing data on 100,000 volunteers, who will be initially screened for three hereditary conditions.Participants in the first part of the study—called Tapestry—will receive screening results for familial hypercholesterolemia, hereditary breast and ovarian cancer (BRCA1 and BRCA2), and Lynch syndrome.
Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer
HK Kim, J Hum Genetics, January 2020
(Posted: Jan-13-2020 9AM)
New PARP Inhibitor Approval for Pancreatic Cancer
L Schlager, FORCE, January 6, 2020
(Posted: Jan-07-2020 8AM)
The Food and Drug Administration approved olaparib– a type of targeted therapy known as a PARP inhibitor—for treatment of metastatic pancreatic cancer in people with a BRCA mutation. PARP inhibitors have been approved to treat ovarian cancer since 2014, and to treat metastatic breast cancer patients with a BRCA mutation since 2018.
Heartbreaking News, Then Tumor Find Leads to Genetic Testing
V Hackethal, Medscape, December 27, 2019
(Posted: Dec-29-2019 8AM)
Genetic testing for breast and ovarian cancer has not always been straightforward, and fast-moving research means that genetic testing is becoming more and more complex all the time.
'Polygenic' analyses may sharpen disease risk predictions.
Kaiser Jocelyn et al. Science (New York, N.Y.) 2019 12 (6472) 1431
(Posted: Dec-21-2019 4PM)
Recent studies show a woman could receive a more individualized, accurate cancer risk estimate by factoring in other gene variants. A preprint posted last month finds that a person's “polygenic” background influences not only the disease risk conferred by a BRCA1 defect, but also risks from single gene mutations linked to colorectal cancer and heart disease.
A Genetic Test Led Seven Women in One Family to Have Major Surgery. Then the Odds Changed.
WSJ, December 20,2019
(Posted: Dec-21-2019 4PM)
Two sisters, their mother and aunts showed a mutation on a BRCA gene and an elevated risk of breast and ovarian cancer
Reducing Disparities in Receipt of Genetic Counseling for Underserved Women at Risk of Hereditary Breast and Ovarian Cancer.
Sutton Arnethea L et al. Journal of women's health (2002) 2019 Nov
(Posted: Dec-11-2019 9AM)
Population based targeted sequencing of 54 candidate genes identifies PALB2 as a susceptibility gene for high grade serous ovarian cancer
MedRXIV, December 2019
(Posted: Dec-07-2019 7AM)
Low rates of cascade genetic testing among families with hereditary gynecologic cancer: An opportunity to improve cancer prevention.
Griffin Natalie E et al. Gynecologic oncology 2019 Nov
(Posted: Dec-04-2019 10AM)
Cascade genetic testing (CGT) of hereditary breast and ovarian cancer (HBOC) or Lynch Syndrome (LS) patients' relatives offers opportunities to prevent cancer, but CGT rates are not well described. We aimed to measure reported disclosure of genetic testing results and CGT rates in these families and evaluate patients' views of educational media.
Retesting of women who are negative for a BRCA1 and BRCA2 mutation using a 20-gene panel.
Lerner-Ellis Jordan et al. Journal of medical genetics 2019 Nov
(Posted: Dec-03-2019 8AM)
Our findings indicate that the retesting of BRCA1/2-negative individuals with an expanded panel of 20 breast and ovarian cancer genes can produce clinically relevant results, with a yield of 5.5% for pathogenic variants in genes other than BRCA1 and BRCA2.
Diagnostic plasma miRNA-profiles for ovarian cancer in patients with pelvic mass.
Oliveira Douglas Nogueira Perez et al. PloS one 2019 (11) e0225249
(Posted: Nov-21-2019 7AM)
CMS Aims to Broaden Coverage for NGS Testing in Breast, Ovarian Cancer -Expansion would include patients with risk factors for inherited susceptibility mutations
I Ingram, MedPage Today, October 31, 2019
(Posted: Nov-05-2019 9AM)
In a proposed decision memo on Tuesday, the agency stated that sufficient evidence exists to support testing when treating physicians determine that patients with breast and ovarian cancer have clinical indications for germline testing, risk factors for an inherited cancer, and have yet to receive such testing.
Year in Review: Ovarian Cancer: PARP inhibitors, genetic testing, and novel combinations
I Ingram, Medpage Today, November 1, 2019
(Posted: Nov-03-2019 7AM)
Two themes dominated the ovarian cancer headlines in 2019 -- moving PARP inhibitors into earlier lines of therapy for advanced-stage disease and genetic testing. Over the summer, the U.S. Preventive Services Task Force (USPSTF) broadened its criteria for BRCA cancer susceptibility gene testing in women.
PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
NCI, October 29, 2019
(Posted: Oct-31-2019 0PM)
Drugs known as PARP inhibitors are used to treat some women with advanced ovarian cancer that has returned after earlier treatment. Now, results from three new clinical trials show that the drugs might also benefit women who are newly diagnosed with advanced ovarian cancer.
Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.
Veneris Jennifer Taylor et al. Gynecologic oncology 2019 Oct
(Posted: Oct-23-2019 8AM)
PARP inhibitors have transformed the management of advanced high-grade serous ovarian cancer. Despite the overwhelming success of PARP inhibition, particularly in BRCA-mutated ovarian cancer, several limitations and unanswered questions remain. The population appropriate to target with PARP inhibitors in patients without BRCA mutations is controversial.
BRCA testing in unaffected young women in the United States, 2006-2017.
Guo Fangjian et al. Cancer 2019 Sep
(Posted: Oct-09-2019 8AM)
Over the past decade, there was increased use of BRCA testing for cancer prevention. Additional efforts are needed to maximize the early detection of women with BRCA pathogenic variants so that these cancers may be prevented.
General “Take Action” Infographic
CDC Cancer, 2019
(Posted: Oct-08-2019 8AM)
Lower your risk of hereditary breast and ovarian cancer. Asking relatives about their cancer histories can be hard. Follow these tips: Share that you have learned that cancers can run in families. Explain that you are creating a record of your family’s history of cancer. •Encourage family members to respond in a way that is most comfortable to them.
A Patient’s Guide to Endometrial Cancer-This cancer is on the rise. But early detection saves lives.
MO Shroeder, US News, October 4, 2019
(Posted: Oct-05-2019 9AM)
Risk factors for this cancer include: obesity, diabetes, having close relatives like a parent or sibling who have endometrial cancer or colorectal cancer, and a genetic condition called Lynch syndrome. Having Lynch syndrome greatly increases a woman’s risk of developing endometrial cancer, and other cancers like colon and ovarian cancer
Population prevalence of individuals meeting criteria for hereditary breast and ovarian cancer testing.
Greenberg Samantha et al. Cancer medicine 2019 Sep
(Posted: Sep-25-2019 9AM)
Randomised trial of population-based BRCA testing in Ashkenazi Jews: long-term outcomes.
Manchanda R et al. BJOG : an international journal of obstetrics and gynaecology 2019 Sep
(Posted: Sep-18-2019 9AM)
Unselected population-based BRCA testing provides the opportunity to apply genomics on a population-scale to maximize primary prevention for breast-and-ovarian cancer. The study compared long-term outcomes of Ashkenazi jewish population-based and family-history (FH)/clinical-criteria-based BRCA testing on psychological health and quality of life
Learn Your Family History of Breast and Ovarian Cancer
(Posted: Sep-16-2019 8AM)
Learning your family history of cancer, from both your mother’s and father’s sides, can help you know if you have a higher risk for getting breast or ovarian cancer at a young age.Asking your relatives about their cancer histories can be hard. Here are some tips for talking with your family about this topic.
What you need to know about ovarian cancer
(Posted: Sep-05-2019 8AM)
There is no way to know for sure if you will get ovarian cancer. Most women get it without being at high risk. However, several factors may increase a woman’s risk for ovarian cancer, including if you are middle-aged or older; have close family members who have had ovarian cancer; have a genetic mutation called BRCA1 or BRCA2, or Lynch syndrome.
Diagnostic significance assessment of the circulating cell-free DNA in ovarian cancer: An updated meta-analysis.
Li Boxuan et al. Gene 2019 Sep 714143993
(Posted: Aug-27-2019 6PM)
USPSTF Recommendation Expands Cancer Screening Pool, Concerns Still Remain
KL Kahl, Cure, August 26, 2019
(Posted: Aug-27-2019 7AM)
Many see the new USPSTF guidelines as a major step forward in genetics. However, the updated recommendation still comes with concerns: It failed to include newly diagnosed patients with breast or ovarian cancer as well as patients with advanced cancers. In addition, it did not include men. Fifty percent of people with a BRCA mutation are men.
Twenty Years of BRCA1 and BRCA2 Molecular Analysis at MMCI - Current Developments for the Classification of Variants.
Machackova Eva et al. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti 2019 32(Supplementum2) 51-71
(Posted: Aug-21-2019 8AM)
Health Care Provider Adherence to Surgical Guidelines for Risk-Reducing Salpingo-Oophorectomy.
Wilhite Annelise M et al. Obstetrics and gynecology 2019 Aug
(Posted: Aug-19-2019 8AM)
In this multicenter retrospective cohort study, women were included if they had a pathogenic BRCA mutation and underwent risk-reducing salpingo-oophorectomy. Despite clear surgical guidelines, only two thirds of all health care providers were fully adherent to guidelines. Gynecologic oncologists were more likely to follow surgical guidelines.
Genetic Testing Can Reduce Suffering and Save Lives
L Corduck, AJMC, August 14, 2019
(Posted: Aug-15-2019 8AM)
I am Oneinforty. In late 2016 at the age of 45, I sought genetic counseling and screening after a friend’s urging. The screening showed I had inherited a BRCA gene mutation, putting my lifetime risk of developing breast cancer between 50% and 80%, and my lifetime risk of developing ovarian cancer (for which there is limited screening) between 40% and 60%.
Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.
Yarmolinsky James et al. PLoS medicine 2019 Aug (8) e1002893
(Posted: Aug-13-2019 8AM)
The study employed mendelian randomization to systematically evaluate the association of 12 previously reported risk factors with risk of invasive epithelial ovarian cancer, invasive epithelial ovarian cancer histotypes, and low malignant potential tumours in up to 25,509 cases and 40,941 controls in the Ovarian Cancer Association Consortium.
PARP Inhibitors Hit the Pancreatic Cancer Scene
D Ternyila, Oncology Nursing News, August 9, 2019
(Posted: Aug-13-2019 8AM)
PARP inhibitors, which have approved indications in breast and ovarian cancer, are expanding to additional treatment paradigms, including pancreatic cancer. Data from the phase III POLO trial showed that PARP inhibitor significantly improved progression-free survival among patients with germline BRCA-mutated metastatic pancreatic cancer.
Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
Krassuski Lisa et al. BMC medical informatics and decision making 2019 Aug 19(1) 154
(Posted: Aug-07-2019 8AM)
Ovarian Cancer Risk Influenced by Vaginal Microbiome?
P Harrison, eMdscape, July 2019
(Posted: Jul-28-2019 4PM)
Lynch Syndrome Screening in Gynecological Cancers: Results of an International Survey with Recommendations for Uniform Reporting Terminology for Mismatch Repair Immunohistochemistry Results.
Ryan Neil et al. Histopathology 2019 Jul
(Posted: Jul-24-2019 10AM)
Infographic: What Every Young Woman Needs to Know About Hereditary Breast and Ovarian Cancer
(Posted: Jul-17-2019 9AM)
The 2019 HBOC and Lynch Syndrome Family Day
Michigan Public Health Institute, Register for event, September 21, 2019
(Posted: Jul-12-2019 8AM)
The 2019 HBOC and Lynch Syndrome Family Day is a patient-focused educational event designed to bring together people and families who have been impacted by hereditary breast and ovarian cancer (HBOC) or Lynch syndrome. Attendees at this free event will learn about hereditary cancer risks and ways to manage risk.
Fifteen-year survival of invasive epithelial ovarian cancer in women with BRCA1/2 mutations - the National Israeli Study of Ovarian Cancer.
Lavie Ofer et al. Gynecologic oncology 2019 153(2) 320-325
(Posted: Jul-10-2019 8AM)
Identifying disparities in germline and somatic testing for ovarian cancer.
Huang Marilyn et al. Gynecologic oncology 2019 153(2) 297-303
(Posted: Jul-10-2019 8AM)
The objectives of this study were to determine the rate of germline and somatic testing in women with ovarian cancer and to identify disparities in testing at a comprehensive cancer center (CCC) and a safety net hospital (SNH).Patients treated for ovarian cancer from 2011 to 2016 were included. There was no difference in germline or somatic testing by race/ethnicity. Disparities in both germline and somatic testing exist
BRCA germline mutation test for all woman with ovarian cancer?
Paradiso A V et al. BMC cancer 2019 Jun 19(1) 641
(Posted: Jul-02-2019 9AM)
Nevada Health Study Using Genetics To Fight Disease Statewide
N Glick, KUNR, June 28, 2019
(Posted: Jul-01-2019 1PM)
The Healthy Nevada Project kicked off in 2016, and so far, has around 50,000 participants. Its aim is to eventually reach 1 million people across Nevada. Anyone can sign up, which is what makes it the largest community-based population health study of its kind in the world. For now, the study is looking for three gene variants that are linked to colon cancer, high cholesterol and breast and ovarian cancer.
Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study.
Harris Holly R et al. International journal of epidemiology 2019 Jun
(Posted: Jun-21-2019 1PM)
Genetic counseling of patients with ovarian carcinoma: acceptance, timing, and psychological wellbeing.
Van de Beek I et al. Journal of community genetics 2019 Jun
(Posted: Jun-12-2019 7AM)
Recommendations for the implementation of BRCA testing in ovarian cancer patients and their relatives.
Gori Stefania et al. Critical reviews in oncology/hematology 2019 May 14067-72
(Posted: Jun-12-2019 7AM)
Universal endometrial cancer tumor typing: How much has immunohistochemistry, microsatellite instability, and MLH1 methylation improved the diagnosis of Lynch syndrome across the population?
Kahn Ryan M et al. Cancer 2019 May
(Posted: Jun-05-2019 9AM)
Tumor-Stroma Proportion as a Predictive Biomarker of Resistance to Platinum-Based Chemotherapy in Patients With Ovarian Cancer
E Lou et al, JAMA Oncology, June 1, 2019
(Posted: Jun-03-2019 10AM)
Developing a culturally targeted video to enhance the use of genetic counseling in Latina women at increased risk for hereditary breast and ovarian cancer.
Hurtado-de-Mendoza Alejandra et al. Journal of community genetics 2019 May
(Posted: May-22-2019 8AM)
Epithelial ovarian cancer risk: a review of the current genetic landscape.
Flaum Nicola et al. Clinical genetics 2019 May
(Posted: May-20-2019 8AM)
Novel Nanochip Paves Way for Early Ovarian Cancer Detection.
Abbasi Jennifer et al. JAMA 2019 May (18) 1759
(Posted: May-16-2019 7AM)
The influence of BRCA variants of unknown significance on cancer risk management decision-making.
Chern Jing Yi et al. Journal of gynecologic oncology 2019 Feb
(Posted: May-15-2019 9AM)
Accuracy in risk understanding among BRCA1/2-mutation carriers.
Speiser Dorothee et al. Patient education and counseling 2019 May
(Posted: May-15-2019 8AM)
Genetic counseling referral for ovarian cancer patients: a call to action.
Garcia Christine et al. Familial cancer 2019 Apr
(Posted: Apr-24-2019 7AM)
Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Tutty Erin et al. European journal of human genetics : EJHG 2019 Apr
(Posted: Apr-10-2019 0PM)
The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome.
Crosbie Emma J et al. Genetics in medicine : official journal of the American College of Medical Genetics 2019 Mar
(Posted: Mar-29-2019 9AM)
"Decoding hereditary breast cancer" benefits and questions from multigene panel testing.
Colas Chrystelle et al. Breast (Edinburgh, Scotland) 2019 Jan 4529-35
(Posted: Mar-06-2019 9AM)
Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
Singer Christian F et al. Cancer medicine 2019 Mar
(Posted: Mar-03-2019 10AM)
Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
Knerr Sarah et al. Journal of the National Cancer Institute 2019 Feb
(Posted: Feb-20-2019 11AM)
Consensus guidelines for genetic testing for hereditary breast and ovarian cancer
American Society for Breast Surgeons, February 14, 2019
(Posted: Feb-16-2019 0PM)
Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
So Min-Kyung et al. Breast cancer (Tokyo, Japan) 2019 Feb
(Posted: Feb-12-2019 10AM)
High-risk breast cancer surveillance with MRI: 10-year experience from the German consortium for hereditary breast and ovarian cancer.
Bick Ulrich et al. Breast cancer research and treatment 2019 Feb
(Posted: Feb-12-2019 10AM)
Challenges and Opportunities for Cancer Predisposition Cascade Screening for Hereditary Breast and Ovarian Cancer and Lynch Syndrome in Switzerland: Findings from an International Workshop.
Nikolaidis Christos et al. Public health genomics 2019 Jan 1-12
(Posted: Jan-30-2019 9AM)
BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
Cline Melissa S et al. PLoS genetics 2018 Dec 14(12) e1007752
(Posted: Jan-02-2019 11AM)
Black and Minority Ethnic women's decision-making for risk reduction strategies after BRCA testing: Use of context and knowledge.
Machirori Mavis et al. European journal of medical genetics 2018 Dec
(Posted: Dec-19-2018 10AM)
Communication About Hereditary Cancers on Social Media: A Content Analysis of Tweets About Hereditary Breast and Ovarian Cancer and Lynch Syndrome.
Allen Caitlin G et al. Journal of cancer education : the official journal of the American Association for Cancer Education 2018 Dec
(Posted: Dec-09-2018 4PM)
Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey Melissa K et al. Cancer 2018 Nov
(Posted: Dec-04-2018 10AM)
Reclassification of BRCA1 and BRCA2 variants of uncertain significance: a multifactorial analysis of multicentre prospective cohort.
Lee Jee-Soo et al. Journal of medical genetics 2018 Nov
(Posted: Nov-14-2018 11AM)
Every Woman Study,
World Ovarian Cancer Coalition Survey, 2018
(Posted: Oct-21-2018 2PM)
Report: Women Everywhere Don't Know Enough About Ovarian Cancer
J Silberner, NPR, October 21, 2018
(Posted: Oct-21-2018 2PM)
Personalised medicine and population health: breast and ovarian cancer.
Narod Steven A et al. Human genetics 2018 Oct
(Posted: Oct-20-2018 4PM)
Gynecological-endocrinological aspects in women carriers of BRCA1/2 gene mutations.
Doren A et al. Climacteric : the journal of the International Menopause Society 2018 Oct 1-7
(Posted: Oct-10-2018 7AM)
Population-based genetic testing of asymptomatic women for breast and ovarian cancer susceptibility.
Rowley Simone M et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 Sep
(Posted: Sep-27-2018 7AM)
The Cost of Ovarian Cancer Prevention- Seven years ago, I was diagnosed with Lynch syndrome, a hereditary cancer condition which significantly increases my chances of developing early-onset cancer.
G Hurst, Cure Magazine, September 24, 2018
(Posted: Sep-26-2018 9AM)
Poly (ADP-ribose) Polymerase Inhibitors in the Management of Ovarian Cancer: A Drug Class Review.
Ringley J Tanner et al. P & T : a peer-reviewed journal for formulary management 2018 Sep (9) 549-556
(Posted: Sep-10-2018 8AM)
Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
Li Jingmei et al. International journal of cancer 2018 Sep
(Posted: Sep-05-2018 9AM)
New Developments in Ovarian Cancer Treatment Are Showing Promise
A Park, Time, August 28, 2018
(Posted: Aug-31-2018 8AM)
BRCA1 and BRCA2 Testing in Medically Underserved Medicare Beneficiaries With Breast or Ovarian Cancer
AL Gross et al, JAMA, August 14, 2018
(Posted: Aug-15-2018 8AM)
Ovarian cancer genetics unravelled
K Wighton, Imperial College, August 13, 2018
(Posted: Aug-14-2018 0PM)
A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos Shoko et al. Critical reviews in oncology/hematology 2018 Jul 12729-41
(Posted: Aug-01-2018 10AM)
Men's and Women's Approaches to Disclosure About BRCA-Related Cancer Risks and Family Planning Decision-Making.
Dean Marleah et al. Qualitative health research 2018 Jul 1049732318788377
(Posted: Jul-29-2018 8PM)
Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap.
McCuaig Jeanna M et al. Journal of medical genetics 2018 Jul
(Posted: Jul-26-2018 7AM)
Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool.
Tea Muy-Kheng M et al. PloS one 2018 13(7) e0200559
(Posted: Jul-18-2018 9AM)
A new bioinformatics tool to help assess the significance of BRCA1 variants.
Cusin Isabelle et al. Human genomics 2018 Jul 12(1) 36
(Posted: Jul-18-2018 9AM)
A qualitative study of barriers to genetic counseling and potential for mobile technology education among women with ovarian cancer.
Vogel Rachel Isaksson et al. Hereditary cancer in clinical practice 2018 13
(Posted: Jul-16-2018 10AM)
Underdiagnosis of Hereditary Breast and Ovarian Cancer in Medicare Patients: Genetic Testing Criteria Miss the Mark.
Yang Shan et al. Annals of surgical oncology 2018 Jul
(Posted: Jul-13-2018 2PM)
Genetic screening can inform women of their breast and ovarian cancer risks
L Abaid, LA Times, July 5, 2018
(Posted: Jul-06-2018 8AM)
Pancreatic cancer as a sentinel for hereditary cancer predisposition.
Young Erin L et al. BMC cancer 2018 Jun 18(1) 697
(Posted: Jul-03-2018 11AM)
Catalysts towards cancer risk management action: A longitudinal study of reproductive-aged women with BRCA1/2 mutations.
Werner-Lin Allison et al. Journal of psychosocial oncology 2018 Jun 1-16
(Posted: Jun-11-2018 11AM)
The uptake of presymptomatic genetic testing in hereditary breast-ovarian cancer and Lynch syndrome: a systematic review of the literature and implications for clinical practice.
Menko Fred H et al. Familial cancer 2018 May
(Posted: Jun-11-2018 11AM)
Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
Elmi Maryam et al. Breast cancer research and treatment 2018 May
(Posted: May-25-2018 8AM)
Previvor: An Oncology Nurse's Story of Cancer Risk Reduction Through Genetic Testing.
Kelly Joanne et al. Clinical journal of oncology nursing 2018 Jun 22(3) 247-248
(Posted: May-23-2018 9AM)
Current clinical topics of Lynch syndrome.
Tanakaya Kohji et al. International journal of clinical oncology 2018 May
(Posted: May-16-2018 9AM)
Validation of Version 3.0 of the Breast Cancer Genetics Referral Screening Tool (B-RST™).
Bellcross Cecelia et al. Genetics in medicine : official journal of the American College of Medical Genetics 2018 May
(Posted: May-11-2018 11AM)
Study Shows Experimental Screening Test Can Detect Endometrial and Ovarian Cancers
NCI, May 2018
(Posted: May-08-2018 8AM)
National Distribution of Cancer Genetic Testing in the United States-
Evidence for a Gender Disparity in Hereditary Breast and Ovarian Cancer
K Childers et al, JAMA Onc, Apr 26, 2018
(Posted: Apr-27-2018 1PM)